Gyre Q2 2026 net loss widens to $14.3M; FY revenue guidance affirmed at $100.5-111.0M

GYRE THERAPEUTICS, INC.

Q2 2026 revenue $29.1M, down 2% YoY; GAAP basic EPS $(0.12); net loss $14.3M vs $2.2M loss in Q2 2025.
Non-GAAP adjusted net loss $12.2M vs $0.6M loss; R&D expense up 129% to $19.1M on F351 and milestone.
Cullgen acquisition closed May 4, 2026, all-stock ~$300M; Dr. Ying Luo now CEO/President, new CSO/CFO named.
NDA for F351 (CHB liver fibrosis) accepted by China's CDE in May 2026; full-year revenue guidance reaffirmed.
Cash, deposits, and investments totaled $103.2M at June 30, 2026, down $12.9M from year-end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.